Current anti-epidermal growth factor receptor (EGFR) therapy for oral cancer does not provide satisfactory efficacy due to drug resistance or reduced EGFR level. As an alternative candidate target for therapy, here we identified an oncogene, ROS1, as an important driver for oral squamous cell carcinoma (OSCC) metastasis. Among tumors from 188 oral cancer patients, upregulated ROS1 expression strongly correlated with metastasis to lung and lymph nodes. Mechanistic studies uncover that the activated ROS1 results from highly expressed ROS1 gene instead of gene rearrangement, a phenomenon distinct from other cancers. Our data further reveal a novel mechanism that reduced histone methyltransferase EZH2 leads to a lower trimethylation of histone H3 lysine 27 suppressive modification, relaxes chromatin, and promotes the accessibility of the transcription factor STAT1 to the enhancer and the intron regions of ROS1 target genes, CXCL1 and GLI1, for upregulating their expressions. Down-regulation of ROS1 in highly invasive OSCC cells, nevertheless, reduces cell proliferation and inhibits metastasis to lung in the tail-vein injection and the oral cavity xenograft models. Our findings highlight ROS1 as a candidate biomarker and therapeutic target for OSCC. Finally, we demonstrate that co-targeting of ROS1 and EGFR could potentially offer an effective oral cancer therapy.
INTRODUCTION
Oral squamous cell carcinoma (OSCC) is the most prevalent (more than 90%) oral cancer. Nearly 145 400 people died of oral cancer and 300 400 new cases occurred globally in 2012. 1 The causes of OSCC include chronic irritation and inflammation from tobacco smoking, alcohol consumption, betel nut chewing, and HPV infection. [2] [3] [4] [5] [6] Inhibitors and blocking antibodies of epidermal growth factor receptor (EGFR) have been used clinically to treat OSCC because EGFR level is elevated in 70-90% of patients with OSCC. 7 However, clinical trials for therapies that target EGFR have not been successful for head and neck cancers. 8 One recent study showed that, among patients exhibiting primary OSCC, their invasiveness correlated inversely with the level of EGFR in cells. 9 This result explains why the response rate for treatment with anti-EGFR (cetuximab) is only 13% for head and neck cancers. 10 Another study demonstrated that only 10-15% of those with Stage I oral cancer responded to erlotinib (EGFR inhibitor), and patients of Stage II-IV did not respond to treatment at all. 11 Findings from these two studies underscore the heterogeneity of oral cancer and reveal that additional factors must be involved in determining the invasiveness of OSCC. Thus, understanding the mechanisms that underlie differential drug sensitivity of OSCC is key to the development of improved therapeutic strategies to circumvent the lack of efficacy for late-stage OSCC patients.
We speculate that, to overcome EGFR resistance, the molecular mechanism may involve compensating for EGFR signaling. Here, we screened the expression of 16 receptor tyrosine kinases (RTKs) that have previously been implicated in tumorigenesis, and found that the oncogene ROS1 is upregulated in highly invasive OSCC. v-ROS was originally identified as an oncogenic RTK encoded in the genome of avian sarcoma virus UR2, [12] [13] [14] and ROS1 is the human homolog of v-ROS, [15] [16] [17] for which the cellular ligand remains unknown. Constitutive activation of ROS1 was resulted from genetic rearrangement in non-small-cell lung cancer, glioblastoma, cholangiocarcinoma, ovarian cancer, and gastric adenocarcinoma. The 5′ fusion partners of ROS1 identified to date include FIG, SLC34A2, CD74, TPM3, SDC4, EZR, LRIG3, KDELR2, YWHAE, TFG, CEP85L, and CCDC6. 18 Although efforts have been devoted to studying the effect of constitutively active ROS1 fusion proteins, the regulation of endogenous ROS1 expression and the role of ROS1 amplification in cancer are not clear. An emerging theme suggests that cancer is a consequence of a dysregulated epigenome, which grants for phenotypic selection in the dynamic microenvironment. 19 Epigenetic modifications confer cancer cell plasticity, thereby allowing cells to circumvent the control of development/differentiation, resulting in cellular heterogeneity.
In this study, we investigated the mechanisms that contributed to the metastasis of OSCC, revealing that upregulated expression of the ROS1 oncogene correlates with metastatic potential and recurrence among 188 OSCC patients. We determined the mechanisms that led to ROS1 upregulation and found that treatment with inhibitors of ROS1 and EGFR dramatically decreased the invasiveness of OSCC and therefore could provide substantial clinical benefits to patients.
RESULTS

Upregulated ROS1 in highly invasive OSCC cells
We have established several isogenic pairs of highly invasive OSCC cell lines through in vitro or in vivo selections. 20 OC3-I5, C9-I7, and SAS-I5 were highly invasive lines derived from their respective parental lines, OC3, C9, and SAS, acquired through serial Boyden chamber invasion assay (in vitro selection). OC3-IV2 and C9-IV2 lines were established from lung metastases after tail vein injection of OC3 or C9 cells into CB17-SCID mice (in vivo selection). The relative invasiveness of these OSCC isogenic lines was compared (Figure 1a) . In clinical practice, anti-EGFR is the most common therapy for oral cancer. 21 Thus, EGFR level in keratinocytes from normal oral mucosa (K2 and K6 cells) and OSCC cell lines were compared. As shown in Figure 1b , EGFR level varied up to 40-fold among the different OSCC cell lines; notably, the levels in the more invasive lines OC3-IV2, C9-IV2, and C9-I7 were lower than those in their respective parental lines OC3 and C9 (Figure 1b) . No obvious difference between SAS and SAS-I5 cells was likely attributed to the constitutively high EGFR levels in these cells. These data suggest that EGFR is not the only candidate biomarker for oral cancer. In fact, reduced EGFR expression correlated with greater invasiveness of OSCC. When treated with the EGFR inhibitor gefitinib (dose range 0.005-2 μM), the proliferation of most OSCC cell lines was reduced 20-30%, whereas C9 and C8 cells were not affected by gefitinib treatment (Figure 1c, left panel) . Gefitinib treatment reduced cell migration and invasion by 20-40% for most OSCC lines (Figure 1c , middle and right panels). Interestingly, both SAS-I5 and HSC3 cells had a relatively high EGFR level, but their sensitivity to gefitinib differed substantially; neither the invasion nor migration capacity of SAS-I5 cells was significantly affected by gefitinib, whereas these abilities were reduced by 50-70% for HSC3 cells (Figure 1c , middle and right panels). These results illustrate that OSCC cells are heterogeneous and that the inhibition of EGFR may not always yield the expected outcomes.
The fold increase of invasiveness was the highest for the OC3 and OC3-IV2 isogenic pair (Figure 1a ), thus they were chosen as : *OC3, SAS, SAS-I5;  # OC3, SAS, SAS-I5, HSC3;   $   OC3, OC3-IV2, C9-IV2, SAS, HSC3. Migration: *C9, C8, SAS-I5, HSC3;   #, $   C9,  C9-IV2, C8, OECM1, SAS-I5, HSC3. Invasion:   *, $   OC3-IV2, C9, C9-IV2, C8, OECM1, HSC3;   #   OC3-IV2, C9 , C8, OECM1, HSC3.) (d) Left: Colony formation assays were performed for 12 days, and the quantification of colony number from three independent experiments is presented as the mean ± SEM. Bottom: proliferation of OC3 and OC3-IV2 cells was assessed using the MTT assays. Proliferation was normalized to that of OC3 cells growing for 24 h. *Comparison between the two cell lines for the same time point. Right: Migration of OC3 and OC3-IV2 cells were determined with the Boyden chamber assays. The quantified results are shown at the bottom. Data from at least three independent experiments are presented as mean ± SEM (* , #, $ Po 0.05).
model cell lines to search for molecules responsible for OSCC invasiveness. Colony formation and MTT assays revealed that OC3 cells proliferated slightly faster than OC3-IV2 cells. Based on Boyden chamber invasion assays, OC3-IV2 cells exhibited significantly increased migration and invasion compared with OC3 cells (Figures 1a and d) . Dysregulated expression and/or activation of RTKs are often associated with malignant transformation. 22, 23 To search for candidate RTKs that may be responsible for the Stage III: primary tumor is more than 4 cm in diameter or cervical lymph node metastasis is detected (metastatic tumor is less than or equal to 3 cm in diameter). Stage IVa: primary tumor invades adjacent tissues and/or cervical lymph node metastasis is detected (metastatic tumor is more than 3 cm in diameter, but less than or equal to 6 cm). Stage IVb: primary tumor invades adjacent tissues and cervical lymph node metastasis is detected (metastatic tumor is more than 6 cm in diameter). ROS1 level in all isogenic OSCC lines compared to the normal and OC3 cells ( Figure 2b , left panel). Likewise, the invasion capacity of C9, OECM1, HSC3, and C8 cells was greater than that of OC3 cells ( Figure 2b , right panel), correlating with the elevated ROS1 level measured in these cells. ROS1 protein level was also examined using tissue arrays containing samples from 64 normal and OSCC subjects; increased ROS1 level strongly correlated with higher metastasis (Figure 2c and Supplementary Figure 2 ). Elevated ROS1 levels were apparent in more than 60% of the oral cancer patients and in 100% Stage IV patients with distant metastasis (Stage IVc). Moreover, ROS1 mRNA level was measured in 23 pairs of matched normal and cancer tissues from OSCC patients from southern Taiwan; ROS1 mRNA was elevated in 15 of 23 patient tissues compared with normal tissues. In addition, 60% of OSCC patients with ROS1 upregulation exhibited lymph node metastasis ( Figure 2d ). In line with those findings, 101 OSCC samples from northern Taiwan also showed a significant correlation between high ROS1 level and metastasis and recurrence (Figures 2e-g ). Our results demonstrate a strong correlation between upregulated ROS1 level and the prevalence of OSCC metastasis. As ROS1 fusions with other genes have been reported in a variety of cancer types, FISH was performed using ROS1 split FISH probes to determine the existence of ROS1 rearrangements in OSCC cell lines and 10 OSCC patient samples. Split signals were not observed, suggesting the lack of ROS1 fusion with any other gene in these cell lines and OSCC patient samples ( Figure 2h ). To confirm this result, we sequenced the 5' region of ROS1 as well as the full-length mRNA; no gene fusion was found (data not shown).
Effect of upregulated ROS1 in migration, invasion and lung colonization of OSCC cells To determine whether our observed upregulated ROS1 level could increase the migration and invasion capacities of OC3-IV2 cells, we established OC3-IV2 cells stably expressing a scrambled shRNA (OC3-IV2-Scr) or ROS1-specific shRNA (OC3-IV2-shROS1#1 and #2). Figure 3f ). These data indicate that ROS1 is required for the increased migration, invasion, proliferation, and lung metastasis of OSCC cells.
Synergistic effect of co-treatment of OSCC cells with gefitinib and either foretinib or crizotinib We next treated OSCC cells with ROS1 inhibitors, foretinib and crizotinib. Cell proliferation was inhibited by 50% at ⩾ 1 μM (Figure 4a ). Cell migration and invasion were significantly inhibited by ⩾ 0.5 μM foretinib (Figure 4b , left panels), yet inhibition was only observed with 2 μM crizotinib (right panels). The differential potency of these two inhibitors echoes published result that foretinib is a relatively more specific ROS1 inhibitor than crizotinib. 24 Based on the above findings, we hypothesized that the ROS1 pathway may compensate for downregulated EGFR signaling or EGFR resistance during late stage of OSCC. OSCC cells were treated with foretinib/crizotinib alone or in combination with 0.1-1 μM gefitinib. Combined treatment with 0.1 μM gefitinib and 0.1-1 μM foretinib or crizotinib resulted in an additional 10-20% inhibition of OC3-IV2 cell proliferation compared with foretinib/ crizotinib alone (Figure 4c ). In contrast, co-treatment with foretinib and gefitinib drastically inhibited cell migration and invasion by 60-80% (Figure 4d) . Similarly, co-treatment with 0.5-2 μM crizotinib and 1 μM gefitinib also synergistically inhibited OSCC cell migration and invasion (Figure 4e ). In addition, co-treatment with foretinib or crizotinib and gefitinib inhibited the proliferation, migration, and invasion capacities of C9 and C9-IV2 cells more so than with foretinib or crizotinib alone (Supplementary Figure 3) . These results demonstrate that ROS1 collaborates with EGFR to promote OSCC cell proliferation, migration, and invasion and that combined treatment with foretinib and gefitinib improves the efficacy of inhibiting highly invasive OSCC.
Epigenetic regulation of ROS1 To understand the mechanisms responsible for the increased ROS1 expression in OSCC tumors, DNA methylation and histone modification at the ROS1 promoter were examined. The CpG islands between nucleotides -384 to -132 within the promoter were previously reported to be the main regulatory region of ROS1. 25 Bisulfite sequencing analysis revealed a comparable degree of methylation at the ROS1 promoter between OC3 and OC3-IV2 cells (Figure 5a ). Thus, DNA methylation is not likely to contribute to the increased expression of ROS1 in OSCC. Histone H3 methylation contributes to either activation or repression of transcription; histone H3 lysine 4 tri-methylation (H3K4me3) represents transcriptional activation, whereas H3K27me3 marks transcriptional repression. [26] [27] [28] [29] ChIP assays were performed to identify histone modifications at the 5' region of ROS1 (Figure 5b ). In OC3-IV2 cells, H3K27me3 in the ROS1 region was decreased compared with OC3 cells (Figure 5c , left panel), whereas H3K4me3 did not differ between the two cell lines (Figure 5c , right panel). It is thus suggested that the reduced H3K27me3 at the 5' region of ROS1 might contribute to increased ROS1 transcription in OC3-IV2 cells. One key enzyme responsible for methylating H3K27 is EZH2 (enhancer of zeste homolog 2), the main enzymatic subunit of the polycomb repressive complex 2. 30 Interestingly, EZH2 level was reduced in OC3-IV2 cells (Figure 5d , left panel), and occupancy by EZH2 within the 5' region of ROS1 was decreased compared to that in OC3 cells (Figure 5d , right panel), consistent with the observed reduction in H3K27me3 (Figure 5c , left panel). Depleting EZH2 also increased the ROS1 level as well as OC3 cell invasiveness (Figure 5e ). These results indicate that reduced EZH2 level in the more invasive OC3-IV2 cells decreased H3K27me3 at the ROS1 promoter, thereby upregulating ROS1 transcription. Similarly, the EZH2 level in C9-IV2 cells was also reduced compared with C9 cells (Figure 5f, left panel) . Moreover, the lower EZH2 level in C9, OECM1, and C8 cells (relative to OC3 cells) correlated well with the increased invasiveness of these cells (Figure 5f) . To understand what led to reduced EZH2, we compared miRNA (miR) expression between OC3 and OC3-IV2 cells using miR arrays. Of the 326 miRs in the array, 119 were upregulated by 41.5-fold in OC3-IV2 cells compared to OC3 cells. Using the miRanda algorithm, 29 candidate miRs were identified based on the binding energy between each miR and EZH2 (ΔG ⩽ -15; Supplementary Figure 4a Figure 4b) . ROS1-associated oncogenic signaling and novel target genes Concurrent with the increased ROS1 in highly invasive OSCC cells, phosphorylation of ROS1 at tyrosine 2274 was also increased, suggestive of elevated activity (Figure 6a) . ROS1 was previously shown to activate the MAPK kinase (MEK)-extracellular signalregulated kinase (ERK1/2) and phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathways. [31] [32] [33] [34] As expected, phosphorylation of ERK1/2 and AKT was increased in OC3-IV2 cells compared to the parental OC3 cells (Figure 6b ). In contrast, phosphorylated STAT3 transcription factor [pSTAT3(Y705)] was reduced in OC3-IV2 cells (Figure 6b ). The reduction of pSTAT3(Y705) may be a result of reduced EGFR level in the more invasive OSCC cells. Clinical data obtained from OSCC and salivary gland cancer samples also showed reduced pSTAT3(Y705). 11, 35 Knockdown of ROS1 reduced pERK1/2 and pAKT (Figure 6c ). Specific inhibition of either MEK-ERK1/2 or PI3K-AKT signaling by U0126 or LY294002 inhibitor (Figure 6d ) reduced the proliferation, migration, and invasion of OC3 and OC3-IV2 cells (Figures 6e-g ).
We next performed microarray analysis and identified candidate metalloproteinases MMPs and cytokines/chemokines that were differentially expressed and likely involved in OSCC invasion. Q-PCR analysis quantified the expression of several MMP genes as well as CCL20, CCR6, CXCL1, and the receptors for CXCL1 (CXCR1/2). Of those, MMP1, MMP3, CXCL1, and CXCR1/2 were upregulated in OC3-IV2 cells, and their expressions were downregulated upon ROS1 knockdown via shROS1 (Figures 7a and b ). In contrast, CCL20 level was not affected by shROS1. Furthermore, the expression of MMP1, MMP3, and CXCL1s was reduced upon inhibition of the PI3K-AKT and/or MEK-ERK1/2 pathways (Figure 7c ). Activation of chemokine signaling is known to increase MMPs and thus cell invasion, 36 therefore it is likely that CXCL1 plays a key role in promoting OSCC cell migration and invasion. To this end, an OC3-IV2 cell line stably expressing CXCL1 shRNA (OC3-IV2-shCXCL1) was established ( Figure 7d) ; CXCL1 knockdown indeed reduced the migration and invasion but not proliferation of OC3-IV2 cells (Figures 7e and f) . These findings clearly demonstrate that ROS1 EZH2-mediated upregulation of ROS1 oncogene C-H Shih et al activates the MEK-ERK1/2 and PI3K-AKT signaling pathways and increases the expression of MMP1, MMP3, CXCL1, and CXCR1/2. Hence, the observed increase in migration and invasion capacities of OC3-IV2 cells is dependent on an increased level of CXCL1 in tumors.
STAT1-mediated regulation of CXCL1 CXCL1 is a target gene of the transcription factors NF-κB and STAT1. 37 Thus, we performed ChIP assays to determine the occupancy of the CXCL1 regulatory region by NF-κB (-78/-68 in CXCL1) and STAT1 (-2610/-2603 and -3421/-3414). Occupancy by NF-κB at the promoter region of ROS1 did not differ between OC3 and OC3-IV2 cells, whereas occupancy by STAT1 was increased in OC3-IV2 cells (Figures 7g and h ). This increased occupancy by STAT1 at the enhancer region of CXCL1 probably resulted from an increase in pSTAT1 in OC3-IV2 cells (Figure 7h, middle left panel) . In line with our finding that CXCL1 was a newly identified target of ROS1, ROS1 knockdown reduced STAT1 occupancy within the CXCL1 enhancer (Figure 7h , middle right panel). Consistent with these data, the occupancy by STAT1 was dependent on ROS1- Effect of ROS1-induced Gli1 expression in cell proliferation and migration/invasion Our results so far imply a substantive contribution of ROS1 to OSCC cell migration and invasion. Nonetheless, depleting ROS1 also reduced OSCC cell proliferation and colonization (Figures 3b-f) , suggesting that ROS1 helps to maintain cell proliferation. Clinical studies have shown that increased nuclear Gli1 correlates with larger primary tumors, lymphatic metastasis, tumor recurrence, and poor prognosis for OSCC patients. 38, 39 Although Gli1 is best known as the principal transcription factor for the canonical Sonic hedgehog (Shh) pathway, it can also be regulated through the non-canonical MEK-ERK1/2 and PI3K-AKT pathways. 40, 41 We tested the possibility that Gli1 acts downstream of ROS1. As shown in Figure 8a , Gli1 protein level indeed was increased in the more invasive OSCC cells. Among other factors acting in the Shh signaling pathway, the expression of SHH and PTCH1 was increased in OC3-IV2 cells compared with OC3 cells, whereas expression of DHH and IHH did not differ between these cell lines. In contrast, GLI2 and SMO expressions were reduced in OC3-IV2 cells (Figure 8b ). Similar to our observed epigenetic regulation of ROS1, ChIP assays revealed that H3K27me3 modification and occupancy by EZH2 at the GLI1 promoter were decreased in the highly invasive OSCC cells (Figure 8c ). STAT1 occupancy of intron 1 of GLI1 was increased, and this increase was inhibited by an inhibitor of the PI3K-AKT pathway (Figure 8d ). ROS1 knockdown reduced GLI1 expression (Figure 8e ) and STAT1 occupancy of GLI1 intron 1 (Figure 8f ), indicating that GLI1 is a novel target gene of ROS1. Consistent with ROS1 acting upstream of Gli1, inhibiting PI3K-AKT significantly reduced Gli1 level (Figure 8g) . Interestingly, neither cell migration nor invasion was affected by Gli1 knockdown (shGli1#1 and #2; Figure 8h) ; rather, cell proliferation and colony formation were reduced (Figure 8i ). These findings support a positive role for Gli1 in maintaining cell proliferation of OC3-IV2 cells and also explain why inhibiting ROS1 reduces cell proliferation. GLI1 expression is regulated by the ROS1-PI3K-AKT pathway, occupancy of GLI1 intron 1 by STAT1, occupancy of the GLI1 promoter by EZH2, and histone H3K27me3 modification at the GLI1 promoter.
DISCUSSION
Quantitative phosphotyrosine profiling of Rat-1 fibroblast cells expressing different ROS1 fusion proteins has led to the identification of diverse tyrosine phosphorylation and signaling pathways. 42 Therefore, it is likely that different ROS1 fusions in various cancer types adopt distinct mechanisms to promote EZH2-mediated upregulation of ROS1 oncogene C-H Shih et al tumorigenesis. To add to the heterogeneity of cancers, this study revealed another form of ROS1 activation without fusion that is required for clonal growth and metastasis of OSCC cells. Mechanistic investigation revealed that loss of EZH2-mediated epigenetic suppression opened up a subset of promoter/intron/ candidate enhancer regions to facilitate STAT1 accessibility and thus enhanced expressions of ROS1 and its target genes. Nonetheless, we cannot rule out other possibilities, such as reduced levels of miRNAs that target ROS1 transcripts or increased expression of a H3K27 demethylase. Both gain-and loss-offunction mutations of EZH2 have been linked to tumorigenesis. [43] [44] [45] As studies have suggested that EZH2 functions to promote cellular stemness or differentiation, evidence so far nevertheless points to its cell type-specific role in fate determination. 30 In a number of OSCC cell lines, knockdown of EZH2 increased invasiveness (Supplementary Figure 5a and b) .
Because EZH2 is a histone methyltransferase, a reduction in cellular EZH2 level could affect several different genes. It is possible that shEZH2 may have affected lineage specificity and/or altered cell morphology, thereby enhancing the expression of stemness genes. Interestingly, the most invasive OSCC-shEZH2 cells were those that had combined elevated expressions of ROS1, GLI1, and CXCL1 ( Supplementary Figure 5c and d) . These findings differ from those reporting an oncogenic role for EZH2 in prostate cancer in that elevated EZH2 level (silences tumor suppressor genes) correlates with metastasis (Supplementary Figure 6a) . Consistent with our results, the level of EZH2 in metastatic lymph nodes of OSCC patients was found to be lower than in primary tumors (Supplementary Figure 6b) . 46 Although Gli1 is best known as a transcription factor involved in the Shh pathway, treatment of OC3 and OC3-IV2 cells with Shh ligand had no effect on their proliferation, migration, or Gli1 level ChIP assays were performed using anti-NF-κB(p65) or anti-STAT1 for IP, followed by Q-PCR. The relative levels of pSTAT1 in OC3 and OC3-IV2 cells were quantified by Western blotting. STAT1 ChIP assays were performed using lysates from OC3-IV2-Scr, OC3-IV2-shROS1, and OC3-IV2 cells treated with 20 μM U0126 or LY294002 for 24 h. Data from at least three independent experiments are presented as mean ± SEM (*P o0.05).
(Supplementary Figure 7) . These results indicate that the observed increased level of Gli1 is not a consequence of activating the canonical Shh pathway. OC3 cells were originally derived from a patient having betel nut-chewing habit but no history of smoking or excessive alcohol consumption. This finding is in line with a previous report suggesting that Shh level is not increased in OSCC caused by betel nut chewing. 38 The current study establishes a strong correlation between elevated expression of the ROS1 oncogene and OSCC metastasis among 188 OSCC patients and a number of OSCC cell lines. The EZH2-mediated change in the epigenome of OSCC cells induces upregulation of ROS1 and its target genes, conferring greater invasiveness and plasticity to cope with the tumor microenvironment. Low EZH2 and enhanced invasiveness are likely attributed to high level of miR-200a-3p. Among the newly identified ROS1 targets, CXCL1, its receptors CXCR1 and CXCR2, MMP1 and MMP3 contribute to cellular invasiveness whereas Gli1, Cyclin D1 and D2 are required for cell proliferation. To circumvent the lack of efficacy of targeting EGFR, co-targeting EGFR and ROS1 provides a novel therapy of treating oral cancer ( Figure 9 ). This study may also provide an improved OSCC treatment regimen by combining ROS1 inhibitor with other therapeutics for those with elevated ROS1.
MATERIALS AND METHODS
Detailed information and procedures for cell proliferation assays, in vitro migration and invasion assays, knockdown of selective genes via RNAi using lentivirus infection, Reverse Transcription-PCR and Q-RCR, Western blotting, FISH, bisulfite sequencing, and ChIP are described in Supplementary Information.
Cell lines
Human oral cancer cell lines OC3, 47 CGHNC9 (C9), 48 CGHNC8 (C8), 48 OECM1, 49 SAS, 50 and HSC3 51 were used. OC3, C9 and C8 cells were derived from OSCC of patients. OECM1 was derived from gingival epidermoid 
Antibodies and reagents
Antibodies against ROS1 (#ab108492) and H3K4me3 (#ab8580) were purchased from Abcam (Cambridge, MA, USA). Antibodies against pROS1 (Y2274) (#3078), pERK1/2 (#9106), pAKT(S473) (#4051), AKT (#9272), STAT3 (#9139), EZH2 (#5246), and Gli1 (#2534) were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibody against pSTAT3 (Y705) (#BS4181) was purchased from Bioworld Technology (Louis Park, MN, USA). Antibody against H3K27me3 (#07-449) was purchased from Merck Millipore. Antibodies against ERK1/2 (#M5670) and GAPDH (#G8795) were purchased from Sigma-Aldrich. Antibodies against STAT1 (#sc-346) and pSTAT1 (#sc-8394) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Alexa Flour 700-conjugated goat anti-mouse IgG secondary antibody (#A21036) was purchased from Invitrogen. IRDye800CW-labeled anti-rabbit secondary antibody (#926-32211) was purchased from LI-COR Biosciences (Lincoln, NE, USA). LY294002 and U0126 were purchased from Calbiochem (San Diego, CA, USA). Foretinib and gefitinib were purchased from ApexBio Technology (Houston, TX, USA). Crizotinib was purchased from Selleckchem (Huston, TX, USA).
IHC analysis and gene expression of patient tissue samples
Two types of human tissue were used for IHC studies. Human oral cancer tissue array slides containing samples for 101 patients were obtained from Taipei Veterans General Hospital, Taipei, Taiwan. This study is approved by Institutional Review Board of Taipei Veterans General Hospital. Commercial tissue array slides containing samples for 64 patients (OR208) was purchased from US Biomax. IHC staining was performed using anti-ROS1
(1:100; ab5512; Abcam) with an automated slide staining system DISCOVERY XT from Ventana Medical Systems, Inc (Roche, Basel, Switzerland). IHC data for ROS1 staining was graded into strong, moderate, and weak categories based on staining intensity. Strong intensity was interpreted as high ROS1 expression, whereas moderate or weak intensity was interpreted as low ROS1 expression. Twenty-three human oral cancer tissue sections containing paired normal and tumor tissue were obtained from the Department of Public Health and Environmental Medicine, Kaohsiung Medical University, Taiwan. ROS1 expression in these tissues was determined via Q-PCR.
Orthotopic and tail-vein injection of OSCC cells into mice
For oral orthotopic and tail-vein xenograft experiments, 1 × 10 6 OC3-IV2-Scr or OC3-IV2-shROS1 cells were harvested and re-suspended in 100 ml PBS. Ten (oral orthotopic) or twelve (tail-vein xenograft) were randomized into two group for cell injection. The cells were injected through the oral buccal mucosa or tail vein of 6-week-old male CB17/lcr-Prkdc scid /Crl mice (BioLasco, Taiwan). Investigators were not blinded to each group. For the oral orthotopic xenograft model, oral tumors were measured by vernier caliper 2.5 months after injection, and tumor volume was calculated as: V = (L × W 2 )/2, where L is length; W is width. For the tail-vein xenograft model, all mice were sacrificed 2.5 months after injection; lungs were harvested, fixed with formalin, sectioned, and subjected to H&E staining. Total areas of metastatic nodules per field were counted using Image J. All procedures were performed according to approved Institutional Animal Care and Use Committee protocols.
miRNA array analysis
The miRNA expression levels between OC3 and OC3-IV2 cells were analyzed using Affymetrix miRNA 2.0 array (Affymetrix, Santa Clara, CA, USA). The experiment was performed at Microarray Core Laboratory, National Health Research Institute, Taiwan.
Statistical analysis
Statistical analysis of all results was carried out using the paired Student's ttest. All values reflect the mean ± S.E.M. of data obtained from at least three independent experiments. Statistical significance was defined as Po0.05. Figure 9 . Schematic model of how ROS1 promotes oral cancer progression. Higher level of miR-200a-3p correlates with low EZH2 and enhanced OSCC invasion. The reduction of EZH2 level in the highly invasive OSCC cells relieves H3K27m3 modification and opens chromatin for transcriptional activation of ROS1 as well as a number of novel ROS1 target genes. Elevated ROS1 activates the MEK-ERK1/2 and PI3K-AKT pathways to increase STAT1 occupancy at the regulatory regions of GLI1 and CXCL1 to promote cell proliferation and invasion.
